Certainly, the recent approval of Tarlatamab, the first BiTE for solid tumors targeting DLL3, a protein found in small cell lung cancer and in pancreatic cancer, opens the possibility of future studies of this BiTE in PaCa. The gene discussed is DLL3; the disease is pancreatic neoplasm.